Loading stock data…
Starling Oncology, Inc. (STLN)
$6.29-0.03 (-0.47%)
Market ClosedLast close Sep 9
Starling Oncology, Inc., an oncology company, provides various oncology services in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
The Oncology Institute, Inc. in the Healthcare sector is trading at $6.29 with a market capitalization of $644M. Wall Street consensus targets $9.00 (5 analysts), implying a +43.1% move over the next 12 months. The stock is currently near its 52-week high of $7.05, remaining 52.3% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +43.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $161.28M↑ | $147.44M↑ | $141.96M↑ | $136.56M↑ | $119.80M |
| Gross Profit | $27.16M↑ | $23.32M↑ | $22.77M↑ | $18.92M↑ | $17.50M |
| Operating Income | -$4.62M↑ | -$6.51M↑ | -$6.91M↑ | -$8.05M↑ | -$11.21M |
| Net Income | -$9.79M↓ | -$2.49M↑ | -$7.51M↑ | -$16.50M↑ | -$17.01M |
Peer Comparison
JNJUNHPFE
Fundamentals
Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-ho...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$644.11M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.44
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
145.67%
Volume
Today's trading volume
846,385
Recent News
Oncology Institute Q2 Earnings Call Highlights
Oncology Institute (NASDAQ:TOI) reported second-quarter revenue growth, positive adjusted EBITDA and an expanded pipeline of value-based oncology contracts as the company announced it has rebranded as Starling Oncology. Chief Executive Officer Dan Virnich said the new name reflects the company’s ev
The Oncology Institute, Inc. (STLN) Reports Q2 Loss, Tops Revenue Estimates
STARLING ONCOLO (STLN) delivered earnings and revenue surprises of -14.29% and +5.55%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?